Paclitaxel in anthracycline-treated breast cancer patients

Palma Pugliese, S. Brugnatelli, M. Giordano, M. Danova, A. De Monte, A. Richetti, S. Fava, E. Rinaldi, V. Fregoni, C. Epifani, A. Riccardi

Research output: Contribution to journalArticlepeer-review


Between May 1995 and July 1997, paclitaxel (TX) (175 mg/m2 by 3 h i.v. infusion every 21 days) was administered to 70 consecutive patients (median age: 57 years) previously treated with the FEC regimen (cyclophosphamide and 5-fluorouracil, 600 mg/m2, plus epirubicin, 60 or 120 mg/m2) as an adjuvant setting or as a first-line therapy for metastatic disease. Sixty-eight patients were evaluable for response, while two died early. Patients received a median of 4.7 (3-12 course) of TX for a total of 211 courses. The overall response and stable disease rate was 54% in 11 patients, who relapsed following adjuvant FEC, and 60% in 57 patients, who received FEC as first treatment for their metastatic disease. No complete respose was obtained. In patients pretreated for metastatic disease, response and stable disease rates were similar irrespective of previous response to FEC. Main hematologic toxicity of TX was of short duration, grade II/III leukopenia (86% of patients) and non-hematologic toxicity was grade II/III peripheral neuropathy, related to the cumulative dose of TX. At this schedule, TX offers a significant rate of partial responses or disease stabilization in patients with metastatic breast cancer previously treated with FEC.

Original languageEnglish
Pages (from-to)915-918
Number of pages4
JournalOncology Reports
Issue number4
Publication statusPublished - 1998


  • Anthracycline
  • Metastatic breast cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Paclitaxel in anthracycline-treated breast cancer patients'. Together they form a unique fingerprint.

Cite this